Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

John M S Bartlett, Alison Munro, David A Cameron, Jeremy Thomas, Robin Prescott, Chris J Twelves

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.
Original languageEnglish
Pages (from-to)5027-35
Number of pages9
JournalJournal of Clinical Oncology
Volume26
Issue number31
DOIs
Publication statusPublished - Nov 2008

Keywords

  • Adult
  • Aged
  • Antibiotics, Antineoplastic
  • Antigens, Neoplasm
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Cyclophosphamide
  • DNA Topoisomerases, Type II
  • DNA-Binding Proteins
  • Disease-Free Survival
  • Epirubicin
  • Female
  • Fluorouracil
  • Gene Amplification
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Ki-67 Antigen
  • Methotrexate
  • Middle Aged
  • Patient Selection
  • Receptor Protein-Tyrosine Kinases
  • Receptor, Epidermal Growth Factor
  • Receptor, erbB-2
  • Receptor, erbB-3
  • Survival Analysis
  • Time Factors
  • Tissue Array Analysis
  • Treatment Outcome
  • Tumor Markers, Biological

Fingerprint Dive into the research topics of 'Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial'. Together they form a unique fingerprint.

Cite this